Cyclobutyrol

Cyclobutyrol

SCHEMBL312912

CCC(C(=O)O)C1(O)CCCCC1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
CHRM4 P08173 1/20 0.36
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP2C19 P33261 1/20 0.34
PPARA Q07869 1/20 0.34
MME P08473 1/20 0.33
TBXAS1 P24557 1/20 0.33
LMNA P02545 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
USP2 O75604 1/20 0.32
CYP1A2 P05177 1/20 0.32
TSHR P16473 1/20 0.32
BLM P54132 1/20 0.32
CACNA2D1 P54289 1/20 0.32
FFAR3 O14843 1/20 0.32
SLC6A2 P23975 2/20 0.31
SLC6A4 P31645 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclobutyrol SCHEMBL9558905 0.98 CHRM2 (0.35) CHRM2CHRM1CHRM3CHRM4ALDH1A1
Cyclobutyrol SCHEMBL28086622 0.98 CHRM2 (0.35) CHRM2CHRM1CHRM3CHRM4ALDH1A1
Cyclobutyrol SCHEMBL10559593 0.98 CHRM2 (0.35) CHRM2CHRM1CHRM3CHRM4ALDH1A1
SCHEMBL314898 0.98 MME (0.34) CHRM2CHRM1CHRM3CHRM4ALDH1A1
SCHEMBL1186169 0.93 TSHR (0.35) CHRM2CHRM1CHRM3CHRM4ALDH1A1
SCHEMBL664693 0.83 CHRM2 (0.35) CHRM2CHRM1CHRM3CHRM4ALDH1A1
Cyclohexane SCHEMBL4027710 0.83 ALDH1A1 (0.38) ALDH1A1L3MBTL1CYP2C19PPARAMME
Cyclobutyrol SCHEMBL1649614 0.82 CHRM2 (0.34) CHRM2CHRM1CHRM3CHRM4ALDH1A1
SCHEMBL10951781 0.80 CA2 (0.42) CHRM2CHRM1CHRM3CHRM4MME
SCHEMBL25429426 0.79 PPARA (0.33) ALDH1A1L3MBTL1CYP2C19PPARAMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180125986-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2018-05-10 US claimed
EP-2501368-B1 A PROCESS FOR CONVERTING A SOLID (METH)ACRYLATE COPOLYMER INTO A DISPERSED FORM BY MEANS OF A DISPERSING AGENT EVONIK ROEHM GMBH (DE) 2018-04-18 EP claimed
US-20160076062-A1 PROCESSING BIOMASS TO OBTAIN HYDROXYLCARBOXYLIC ACIDS XYLECO, INC. 2016-03-17 US claimed
US-9284416-B2 Process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent EVONIK ROEHM GMBH (DE) 2016-03-15 US claimed
CN-105247060-A Processing biomass to obtain hydroxycarboxylic acids XYLECO INC 2016-01-13 CN claimed
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2015-11-19 US claimed
EP-2890794-A2 PROCESSING BIOMASS TO OBTAIN HYDROXYLCARBOXYLIC ACIDS Xyleco, Inc. (US) 2015-07-08 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2014176508-A2 PROCESSING BIOMASS TO OBTAIN HYDROXYLCARBOXYLIC ACIDS XYLECO, INC. (US) 2014-10-30 WO claimed
WO-2014111957-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS SATYAM APPARAO (IN) 2014-07-24 WO claimed
US-20120208832-A1 PROCESS FOR CONVERTING A SOLID (METH)ACRYLATE COPOLYMER INTO A DISPERSED FORM BY MEANS OF A DISPERSING AGENT EVONIK ROEHM GMBH (DE) 2012-08-16 US claimed
WO-2011057676-A1 A PROCESS FOR CONVERTING A SOLID (METH)ACRYLATE COPOLYMER INTO A DISPERSED FORM BY MEANS OF A DISPERSING AGENT EVONIK RÖHM GMBH (DE) 2011-05-19 WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125986-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, NOS3 CHRM2 549/4885CHRM1 379/4885CHRM3 477/4885
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, PTGIS CHRM2 495/4885CHRM1 361/4885CHRM3 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.